ATRA
Price:
$9.47
Market Cap:
$46.55M
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of...[Read more]
Industry
Biotechnology
IPO Date
2014-10-16
Stock Exchange
NASDAQ
Ticker
ATRA
According to Atara Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 104.92M. This represents a change of -88.95% compared to the average of 949.30M of the last 4 quarters.
The mean historical Enterprise Value of Atara Biotherapeutics, Inc. over the last ten years is 7.39B. The current 104.92M Enterprise Value has changed 42.04% with respect to the historical average. Over the past ten years (40 quarters), ATRA's Enterprise Value was at its highest in in the September 2018 quarter at 18.41B. The Enterprise Value was at its lowest in in the September 2014 quarter at 124.52M.
Average
7.39B
Median
6.03B
Minimum
575.00M
Maximum
15.16B
Discovering the peaks and valleys of Atara Biotherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.46%
Maximum Annual Enterprise Value = 15.16B
Minimum Annual Increase = -82.70%
Minimum Annual Enterprise Value = 575.00M
Year | Enterprise Value | Change |
---|---|---|
2023 | 575.00M | -82.70% |
2022 | 3.32B | -77.36% |
2021 | 14.68B | 2.43% |
2020 | 14.33B | 70.84% |
2019 | 8.39B | -44.66% |
2018 | 15.16B | 184.62% |
2017 | 5.33B | 32.11% |
2016 | 4.03B | -40.11% |
2015 | 6.73B | 413.22% |
2014 | 1.31B | 2.46% |
The current Enterprise Value of Atara Biotherapeutics, Inc. (ATRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.19B
5-year avg
8.26B
10-year avg
7.39B
Atara Biotherapeutics, Inc.’s Enterprise Value is less than Fate Therapeutics, Inc. (449.69M), less than Sana Biotechnology, Inc. (1.08B), less than Caribou Biosciences, Inc. (144.89M), less than Arcus Biosciences, Inc. (1.29B), less than Heron Therapeutics, Inc. (433.33M), less than Allogene Therapeutics, Inc. (427.50M), greater than BioXcel Therapeutics, Inc. (69.61M), less than Karyopharm Therapeutics Inc. (201.87M), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than HOOKIPA Pharma Inc. (87.25M), less than Mereo BioPharma Group plc (582.99M), greater than Galera Therapeutics, Inc. (-5475585.00), greater than Acumen Pharmaceuticals, Inc. (93.64M), less than VectivBio Holding AG (848.58M), less than Icosavax, Inc. (713.87M), less than Apellis Pharmaceuticals, Inc. (5.11B), less than iTeos Therapeutics, Inc. (294.94M), less than TScan Therapeutics, Inc. (142.92M),
Company | Enterprise Value | Market cap |
---|---|---|
449.69M | $386.05M | |
1.08B | $1.12B | |
144.89M | $155.42M | |
1.29B | $1.44B | |
433.33M | $273.00M | |
427.50M | $503.96M | |
69.61M | $22.26M | |
201.87M | $91.04M | |
40.79M | $109.78M | |
87.25M | $159.50M | |
582.99M | $664.26M | |
-5475585.00 | $4.08M | |
93.64M | $133.38M | |
848.58M | $1.06B | |
713.87M | $769.04M | |
5.11B | $5.00B | |
294.94M | $540.52M | |
142.92M | $294.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atara Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Atara Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Atara Biotherapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?
What is the 3-year average Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?
What is the 5-year average Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?
How does the current Enterprise Value for Atara Biotherapeutics, Inc. (ATRA) compare to its historical average?